Get started
Author

Joslyn S. Kirby

Observed names: J. Kirby, J. S. Kirby, J. Sciacca Kirby, J., Kirby, J.S. Kirby, Joslyn Kirby, Joslyn R. S. Kirby, Joslyn S Kirby, Joslyn Sciacca Kirby, Joslyn Sciacca-Kirby, Joslyn Sciacca Kirby, Joslyn S Kirby, Joslyn S. Kirby, Kirby, J., Kirby, J.S., Kirby, Joslyn, Kirby, Joslyn S, Kirby, Joslyn S., Kirby, Joslyn Sciacca
Observed institutions: Hershey (United States), Pennsylvania State University, National and Kapodistrian University of Athens, Hospital of the University of Pennsylvania, Penn State Cancer Institute, University of Pennsylvania, Penn State Milton S. Hershey Medical Center, Incyte (United States)
ORCID: 0000-0002-6741-3796
Observed ORCID: 0000-0002-6741-3796
OpenAlex ID: A5000796908
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations
2019 · Ali Alikhan, Christopher Sayed, et al. · Journal of the American Academy of Dermatology · 400
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations
2019 · Ali Alikhan, Christopher Sayed, et al. · Journal of the American Academy of Dermatology · 399
Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States
2017 · Amit Garg, Joslyn S. Kirby, et al. · JAMA Dermatology · 394
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project
2019 · Amit Garg, Erica Neuren, et al. · Journal of the American Academy of Dermatology · 291
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations
2021 · Amit Garg, Neeta Malviya, et al. · Journal of the American Academy of Dermatology · 239
PDF
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 · Alexa B Kimball, Gregor B E Jemec, et al. · The Lancet · 196
What causes hidradenitis suppurativa ?—15 years after
2020 · Christos C. Zouboulis, Farida Benhadou, et al. · Experimental Dermatology · 192
PDF
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process
2018 · L. Thorlacius, J.R. Ingram, et al. · British Journal of Dermatology · 180
PDF
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
2021 · Falk G. Bechara, Maurizio Podda, et al. · JAMA Surgery · 167
PDF
Health Care Utilization Patterns and Costs for Patients With Hidradenitis Suppurativa
2014 · Joslyn S. Kirby, Jeffery J. Miller, et al. · JAMA Dermatology · 125
The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials
2019 · J.S. Kirby, L. Thorlacius, et al. · British Journal of Dermatology · 121
Laboratory Monitoring During Isotretinoin Therapy for Acne
2015 · Young H. Lee, Thomas P. Scharnitz, et al. · JAMA Dermatology · 121
PDF
Intralesional chemotherapy for nonmelanoma skin cancer: A practical review
2010 · Joslyn S. Kirby, Christopher J. Miller · Journal of the American Academy of Dermatology · 106
A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa
2009 · Robert A. Lee, Erica Dommasch, et al. · Journal of the American Academy of Dermatology · 105
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies*
2022 · Afsaneh Alavi, Iltefat Hamzavi, et al. · British Journal of Dermatology · 94
Standardized laboratory monitoring with use of isotretinoin in acne
2016 · Timothy J. Hansen, SaraMarian Lucking, et al. · Journal of the American Academy of Dermatology · 86
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study
2023 · Joslyn S. Kirby, Martin M. Okun, et al. · Journal of the American Academy of Dermatology · 78
Association of Resilience With Depression and Health-Related Quality of Life for Patients With Hidradenitis Suppurativa
2017 · Joslyn S. Kirby, Melissa Butt, et al. · JAMA Dermatology · 78
PDF
Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa
2015 · Amrit Khalsa, Guodong Liu, et al. · Journal of the American Academy of Dermatology · 75
Self-Healing Collodion Membrane and Mild Nonbullous Congenital Ichthyosiform Erythroderma Due to 2 Novel Mutations in the ALOX12B Gene
2008 · Mandy Harting, Nicola Brunetti-Pierri, et al. · Archives of Dermatology · 72
Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies
2022 · Stephanie L Schell, Zhaoyuan Cong, et al. · British Journal of Dermatology · 65
Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa
2022 · Samuel Der Sarkissian, Schapoor Hessam, et al. · JAMA Dermatology · 61
Loss of Skin Microbial Diversity and Alteration of Bacterial Metabolic Function in Hidradenitis Suppurativa
2019 · Andrea M. Schneider, Lauren C. Cook, et al. · Journal of Investigative Dermatology · 55
Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes
2024 · Alexa B. Kimball, Joslyn Kirby, et al. · Dermatology and Therapy · 54
PDF
Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary
2021 · John W. Frew, Michelle Anne Lowes, et al. · JAMA Dermatology · 54
PDF
Works count: 227
Citation count: 5,270
H-index: 33
I10-index: 82
Year
Topic
Type